Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Protocol ID
CONNECT2108
Disease (Sub Disease)
Adamantinomatous Craniopharyngioma
Diagnosis Stage
Relapsed/refractory
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Nationwide Children's Hospital
Collaborators
Children's Hospital Colorado
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 25 Years
International registry ID's
NCT05286788
Back to Registry
Study Title Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Protocol ID CONNECT2108
Disease (Sub Disease) Adamantinomatous Craniopharyngioma
Diagnosis Stage Relapsed/refractory
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Nationwide Children's Hospital/
Collaborators Children's Hospital Colorado
Links https://clinicaltrials.gov/ct2/show/NCT05286788
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 2
Age Eligibility 1 Year to 25 Years
International registry ID's NCT05286788